The next evolution of truFlex fortifies its position as a versatile solution for rehabilitation with new applications in functional strength for the abdomen, arms, calves, glutes and thighs.
An 8-year-old boy made medical history thanks to Columbus doctors. Yet the city where it happened barely registered. Time we ...
Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over two years old.
A new review of studies reveals that incorporating SMA into newborn screening programs yields clinical improvements and ...
Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.
A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would ...
Loss of muscle mass, also called muscle wasting or atrophy, can happen gradually as part of getting older or more suddenly ...
The effects allowed these minors who could sit but not stand to move like they've never done before, including walking and ...
The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal ...
A single-dose gene replacement therapy is found to improve movement ability in children over 2 years of age and teenagers with spinal muscular atrophy, according to research published in Nature ...
Spinal muscular atrophy (SMA) is a hereditary neuromuscular disorder characterized by progressive muscle weakness, which is caused by the gradual loss of the motor neurons that control the muscles. In ...
The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 gene mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results